75 related articles for article (PubMed ID: 18180602)
1. Combined use of teriparatide and TNFalpha blockade: safety.
Migliore A; Massafra U; Capuano A; Martin SM
Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):18-20. PubMed ID: 18180602
[TBL] [Abstract][Full Text] [Related]
2. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
3. The teriparatide in the treatment of severe senile osteoporosis.
Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
[TBL] [Abstract][Full Text] [Related]
4. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide.
Maugeri D; Russo E; Luca S; Leotta C; Mamazza G; Sorace R; Rizzotto M; Manuele S; Fiore V; Taverna G; Castiglia B; Calitro M
Arch Gerontol Geriatr; 2009; 49(1):35-8. PubMed ID: 18555544
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
Hashimoto Y; Wakayama N; Miyauchi A
Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
[TBL] [Abstract][Full Text] [Related]
7. Nonuremic calciphylaxis in a patient with rheumatoid arthritis and osteoporosis treated with teriparatide.
Dominguez AR; Goldman SE
J Am Acad Dermatol; 2014 Feb; 70(2):e41-2. PubMed ID: 24438979
[No Abstract] [Full Text] [Related]
8. Initial experience with teriparatide in the United States.
Gold DT; Pantos BS; Masica DN; Misurski DA; Marcus R
Curr Med Res Opin; 2006 Apr; 22(4):703-8. PubMed ID: 16684431
[TBL] [Abstract][Full Text] [Related]
9. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.
Tashjian AH; Gagel RF
J Bone Miner Res; 2006 Mar; 21(3):354-65. PubMed ID: 16491282
[No Abstract] [Full Text] [Related]
10. Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment.
Levälampi T; Korpela M; Vuolteenaho K; Moilanen E
Scand J Rheumatol; 2008; 37(1):6-12. PubMed ID: 18189188
[TBL] [Abstract][Full Text] [Related]
11. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide: new indication. During corticosteroid therapy: no fewer clinical fractures. Unnecessarily inconvenient.
Prescrire Int; 2009 Aug; 18(102):159. PubMed ID: 19743573
[No Abstract] [Full Text] [Related]
14. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry.
Coulson KA; Reed G; Gilliam BE; Kremer JM; Pepmueller PH
J Clin Rheumatol; 2009 Jun; 15(4):155-60. PubMed ID: 19363452
[TBL] [Abstract][Full Text] [Related]
15. Patient experience with a new teriparatide delivery device.
Dore RK; Feldman RG; Taylor KA; See K; Dalsky GP; Warner MR
Curr Med Res Opin; 2009 Oct; 25(10):2413-22. PubMed ID: 19656016
[TBL] [Abstract][Full Text] [Related]
16. Paricalcitol, a synthetic vitamin D analog: a candidate for combination therapy with biological agents in rheumatoid arthritis.
Kim TH; Ji JD
Med Hypotheses; 2010 Dec; 75(6):634-5. PubMed ID: 20736134
[TBL] [Abstract][Full Text] [Related]
17. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
18. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
[TBL] [Abstract][Full Text] [Related]
19. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
[TBL] [Abstract][Full Text] [Related]
20. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
